| Ian M Corcoran-schwartz, MD | |
|
2222 Welborn St, Tsrh - Department Of Orthopaedic Surgery, Dallas, TX 75219-3924 | |
| (214) 559-8430 | |
| (214) 559-7570 |
| Full Name | Ian M Corcoran-schwartz |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | 2222 Welborn St, Dallas, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932469327 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | R3816 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ian M Corcoran-schwartz, MD 2222 Welborn St, Department Of Orthopaedic Surgery, Dallas, TX 75219-3924 Ph: (214) 559-8430 | Ian M Corcoran-schwartz, MD 2222 Welborn St, Tsrh - Department Of Orthopaedic Surgery, Dallas, TX 75219-3924 Ph: (214) 559-8430 |
News Archive
Critics of the Democrats' health care overhaul effort see veiled "rationing" schemes behind plans to curb misused and overused tests, treatments and drugs that drive up medical costs without helping patients, The Washington Post reports.
An Italian research team confirmed that the scoring system for Wilson's disease (WD) provides good diagnostic accuracy with 93% positive and 92% negative predictive values, respectively in children with mild liver disease. In asymptomatic children, a urinary copper excretion above 40 μg/24 hours was suggestive of WD, however the penicillamine challenge test (PCT) did not provide an accurate diagnosis in this patient subset.
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs called ImmTACs to treat cancer and viral disease, today announced it has entered into a partnership with GlaxoSmithKline (GSK) for multiple novel targets not addressable using antibody-based technologies. This is Immunocore's second major partnership this year.
Industry Standard Research (ISR) today announced the release of The State of Biomarkers in Drug Development report. 44 pharmaceutical and biotechnology professionals provided their strategies, insights, and predictions in this snapshot of a rapidly evolving market. In total, 37 significant pharma and biotech companies contributed to this endeavor.
NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the completion of patient enrollment in its Phase 2 clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).
› Verified 4 days ago
Dr. Christopher Michael Sakowski, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 7115 Greenville Ave Ste 310, Dallas, TX 75231 Phone: 214-265-3200 Fax: 214-265-3285 | |
Sumant G Krishnan, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 9301 N Central Expy, Suite 400, Dallas, TX 75231 Phone: 214-220-2468 Fax: 214-397-1555 | |
Jorge Casas, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 12222 N Central Expy, Suite 210, Dallas, TX 75243 Phone: 214-615-1949 Fax: 214-615-1949 | |
Nathan Bruck, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 411 N Washington Ave Ste 7000, Dallas, TX 75246 Phone: 214-823-7090 Fax: 214-823-1644 | |
Dr. Michael Wheeler, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8210 Walnut Hill Ln Ste 130, Dallas, TX 75231 Phone: 214-750-1207 Fax: 214-750-8504 | |
Dr. Richard S Levy, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 6901 Snider Plz, Ste 200, Dallas, TX 75205 Phone: 214-369-7733 Fax: 214-360-9604 | |
Dr. Robert Russell Scheinberg, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8210 Walnut Hill Ln, Ste 130, Lb 11, Dallas, TX 75231 Phone: 214-750-1207 Fax: 214-739-5029 |